GlassScriptPhysician profile
Lee H Bogart
NPI 1679554380
$3,577.33
in general payments reported to CMS, 2019-2025
48 companies · $690 in 2025
The $690 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,741 · 2020: $498 · 2021: $11.92 · 2022: $152 · 2023: $89.51 · 2024: $395 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $341.10 | 2019-2025 | |
| Janssen Biotech, INC. | $291.93 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Daiichi Sankyo INC. | $231.49 | 2020-2025 | Enhertu, Injectafer |
| Genentech USA, INC. | $199.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $182.77 | 2019-2020 | |
| Galvanize Therapeutics, INC | $152.02 | 2022 | |
| Celgene Corporation | $146.64 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Pharmaceuticals, INC | $137.99 | 2019-2020 | |
| Lilly USA, LLC | $129.59 | 2019-2020 | |
| Pfizer INC. | $107.80 | 2019-2025 | |
| Gilead Sciences, INC. | $100.06 | 2019-2021 | |
| Eisai INC. | $99.77 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $97.86 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $97.76 | 2019-2025 | Onivyde |
| Genzyme Corporation | $95.91 | 2019-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Bogart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.